← Leaderboards
David Zaharoff
National Cancer Institute
$4,304,118
Attributed
$5,629,071
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,629,071 · 6
By mechanism
U01$2,649,907 · 1
R01$1,511,349 · 1
K22$505,407 · 1
R15$416,897 · 1
R41$398,039 · 1
F32$147,472 · 1
Top collaborators
- Paul R Hess4 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseImmunotherapyImmunityMalignant NeoplasmsCytokineInterleukin-12DesignCancer ImmunotherapyPreclinical StudyChitosanBiopolymersT-LymphocyteSiteImmune ResponseFlow CytometryIn VitroImmuneSerumDrug KineticsSafetyCellsPreventBase
Grant awards (17)
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma$1,081,084
U01 · FY2025 · CA · contact PI
Development of Localized Triple-Negative Breast Cancer Immunotherapy$398,039
R41 · FY2025 · CA · contact PI
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma$507,574
U01 · FY2024 · CA · contact PI
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma$522,345
U01 · FY2023 · CA · contact PI
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma$538,904
U01 · FY2022 · CA · contact PI
Biopolymer-based strategies for local delivery of cytokine therapeutics$302,301
R01 · FY2018 · CA · contact PI
Biopolymer-based strategies for local delivery of cytokine therapeutics$302,644
R01 · FY2017 · CA · contact PI
Biopolymer-based strategies for local delivery of cytokine therapeutics$302,870
R01 · FY2016 · CA · contact PI
Biopolymer-based strategies for local delivery of cytokine therapeutics$302,145
R01 · FY2015 · CA · contact PI
Intravesical Chitosan/IL-12 Immunotherapy for Bladder Carcinoma$416,897
R15 · FY2014 · CA · contact PI
Biopolymer-based strategies for local delivery of cytokine therapeutics$301,389
R01 · FY2014 · CA · contact PI
Chitosan-based Delivery and Immunopotentiation of Cancer Vaccines$168,846
K22 · FY2012 · CA · contact PI
Chitosan-based Delivery and Immunopotentiation of Cancer Vaccines$169,977
K22 · FY2011 · CA · contact PI
Chitosan-based Delivery and Immunopotentiation of Cancer Vaccines$166,584
K22 · FY2010 · CA · contact PI
Mucosal Delivery Strategies for Cancer Vaccines$50,948
F32 · FY2008 · CA · contact PI
Mucosal Delivery Strategies for Cancer Vaccines$49,328
F32 · FY2007 · CA · contact PI
Mucosal Delivery Strategies for Cancer Vaccines$47,196
F32 · FY2005 · CA